JA Cyprus’ Post

#EUfunded Project Spotlight 🇪🇺 👉 EUCANCan 🦾 Mission: To interconnect European and Canadian infrastructures for the analysis and management of #GenomicData in #Oncology. The end result? An open and accessible data portal to fuel future #research towards the identification of clinically relevant patterns of variation in the #CancerGenome, such as #biomarkers predictive of therapeutic response. 🧑⚕️ EUCANCan's consortium was formed of 18 leading organizations from 5 different countries: Barcelona Supercomputing Center (coordinator), DKFZ German Cancer Research Center, Ontario Institute for Cancer Research, CNRS, Hartwig Medical Foundation, Centre for Genomic Regulation (CRG), EMBL, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut Català d 'Oncologia, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Heidelberg (UKHD), Charité - Universitätsmedizin Berlin, Institut Curie, McGill University, Universidad del País Vasco/Euskal Herriko Unibertsitatea, Heidelberger Akademie der Wissenschaften, LINQ management GmbH and Steinbeis GmbH & Co. KG für Technologietransfer. Funded by European Commission under the #H2020 program, as part of the topic: ‘International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches’ We encourage our #GenoMed4All community to learn more about this initiative, which finished in June 2023 and shared some key values and objectives with our mission to advance #PrecisionMedicine by harnessing the power of #Genomics and #AI 👇 https://lnkd.in/eyfvKQG4

Meet Alimzhan Kassabayev from Kazakhstan! 🌟 As the Europe Global Quarter Finals approach, Alimzhan is gearing up to showcase his groundbreaking innovation, OncoZero.AI, at the competition! 🚀 A student at the University of Warwick and the brains behind OncoZero.AI, Alimzhan is revolutionizing early cancer diagnosis. 🩺💡 OncoZero.AI is an advanced online platform powered by the OncoZero.V1 neural network, which analyzes CT scans with an impressive 90% accuracy rate in detecting cancerous tumors. 🧠💻 By doubling the speed of the diagnostic process, OncoZero.AI is not only lightening the workload for doctors but also significantly increasing hospital throughput. 🏥 The impact of OncoZero.AI extends beyond medical processes; it's about saving lives. With the potential to reduce the 5-year mortality rate from 50% to an astounding 25-30%, Alimzhan is on a mission to transform cancer diagnosis and care. 🌟👩⚕️ Best of luck to Alimzhan as he competes in the Europe Global Quarter Finals! 🙌 #EO #GSEA #Innovation #CancerDetection #HealthTech

Mar 20 - #SBIR experts from the National Cancer Institute (NCI) will discuss new funding opportunities for academic innovators, researchers, and entrepreneurs. 1-on-1 meetings to discuss specific projects are still available, but going fast. Click on the link to sign up https://bit.ly/4bS0Nfr Topics include: *SBIR/STTR eligibility requirements *NIH SBIR/STTR process and new cancer-focused funding opportunities from NCI *NCI SBIR/STTR initiatives such as the I-Corps at NIH Entrepreneurship Program, Applicant Assistant Program, etc. *Practical strategies on how to successfully submit competitive research proposals Portal Innovations, LLC @theNCI #ChicagoBiotech #innovation #cancer

🥁 “TreeMHN’s computational method represents outstanding progress in the life science field. It enables a better processing of single cell-based tumor mutation data for the representation and potentially prediction of cancer trajectories.”  ‘Mining tumor mutation trees for evolution-guided precision oncology’ is one of the #SIBRemarkableOutputs 2023 👏 This work joins the yearly list of outstanding contributions from SIB Members across Switzerland to the field of #bioinformatics. 👉 Discover this shortlist of outstanding works: https://lnkd.in/eSPfukcP #TumorMutation #SingleCell #Oncology #CancerResearch 💡The SIB Remarkable Outputs gather on a shortlist the most outstanding works produced by SIB members each year. These contributions showcase the latest advances in the Swiss bioinformatics field and include innovative solutions to share with the life science community. Xiang Ge (Xiangge) Luo ETH Zürich BioAlps - Swiss Health Valley ELIXIR Life Sciences Switzerland (LS2) Luciano Cascione Laurent Falquet Robert Ivánek Charlotte Soneson Patricia Palagi Graf Frederique Lisacek Robert Waterhouse

Today I had the privilege of presenting an exciting project I've been working on alongside the incredible Paula García Sacristán, MSc in the intramural session at GENYO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research. 👨🏻🔬👩🏽🔬 Our work focused on the development of a novel nanodevice tailored for enhanced targeting of T cells, using a ligand-based targeting approach. I also showed the results related to the fully physicochemical and preclinical characterization of the developed nanoparticles, and the evaluation of their its innocuousness, specificity and efficiency in in vitro models, including primary cell lines, and in vivo models. This research not only attempts an intellectual challenge but also promises significant breakthroughs in the fields of medicine and cell therapy. During the session, we explored the intricacies of our project, highlighting the innovation behind the nanoparticles and their potential impact on strengthening cancer medicine. This work wouldn't have been possible without the support of a dedicated and passionate audience at GENyO. I'm grateful for the opportunity to share our findings with colleagues and friends at the center. Today marks my last talk at GENyO, and I'm thrilled to announce that exciting news are on the horizon! ✨ #ScientificResearch #Preclinical #PrecisionMedicine #Immunotherapy #InnovativeScience

New beam time for radiation-biology at GANIL with 13C last week. All projects engaged; all team members concerned A huge and exhausting experiment for our team with 56 uninterrupted hours of beam time, shared during 3 days between master students, PhD students, Post-docs and researchers in physics and biology 💪 💪 Glioblastoma, chondrosarcoma, rhabdomyosarcoma, lung cancer cells, etc… were all irradiated at different doses and dose-rate, sometimes with drugs. Now let’s analyze the results! CIMAP-ARIA team -> https://lnkd.in/eJfjcRGE CIRIL-iRiA platform -> https://lnkd.in/eeeC7d7H https://lnkd.in/eb63rrhD   #GANIL #CIMAP #UHDR #iRiA #hadronbiology

Pre-Cure 's latest achievement is a nod to the resilience of Israeli high-tech—persistently innovating! The new company, recently established, is making its mark. Straight from Prof. Ofra Benny’s Lab at The Hebrew University of Jerusalem: Eliana Steinberg's article, "A fully 3D-printed versatile tumor-on-a-chip for multi-drug screening," is now published in Communications Biology - Nature. Pre-Cure's groundbreaking 3D-printed tumor-on-a-chip facilitates multi-drug screening and correlation with clinical outcomes, providing a cost-effective, transparent, biocompatible, and versatile microfluidic platform. Testing with patient-derived multicellular spheroids demonstrates its potential as a predictive tool for personalized cancer medicine. This research milestone is a triumph in personalized medicine. Dive into the full article here: https://rdcu.be/dqYIL Stay connected with us: https://bit.ly/yissum #ResearchMilestone #NatureJournal #TransformingHealthcare #weareone #nomatterwhat

During her secondment at Miltenyi Biotec headquarters in Bergisch Gladbach, ESR 11 Laura Marcos Kovandzic cooperated with ESR 13 Valeria Durante to perform experiments using the MACSima™ system. Miltenyi Biotec’s MICS (MACSima™ Imaging Cyclic Staining) technology enables the simultaneous analysis of hundreds of markers on a single sample. Based on fluorescence microscopy, it uses the principle of cyclic staining with different fluorochrome-conjugated antibodies to acquire microscopy data for a multitude of parameters without harming the sample. The cyclic process includes three main steps, all conducted automatically by the MACSima™ System. As part of her PhD project, which focuses on studying the impact of gut microbiota on the efficacy of CAR-T cell therapy, Laura and Valeria collaborated through all phases of the experiment. This included antibody panel design, experiment preparation and execution, and analysis of the results using MACS® iQ View iQ View Spatial Biology software. Their aim was to determine the level of CAR-T cell infiltration and proliferation, and to further assess the phenotype of the various infiltrating cells in different treatment groups of samples from in vivo experiments performed in mice. #cancer #research #eu #mariecurie #network

Health Innovation! We were on a technical visit to the Paul Scherer Institut (PSI), in Switzerland. In the area of Health Innovation, several research groups at PSI are engaged in the study of fundamental questions regarding biology and cancer treatment. New approaches to cancer treatment! As far as application-orientated research is concerned, researchers are focusing their attention on the diagnosis and therapy of cancerous diseases. In collaboration with university hospitals, they are concentrating on methods of tumour diagnosis and treatment where PSI's particle beams are most beneficial, with collaboration between experts in different technical fields playing a particularly important role. Proton beam therapy for cancer and the development of modern radiopharmaceuticals for the diagnosis and treatment of tumours fall into this area of study.